Skip to main
DBD

DBD Stock Forecast & Price Target

DBD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Diebold Nixdorf is supported by improving execution, tighter cost controls, and expanding margin visibility across both Banking and Retail, with management maintaining 2026/2027 adj. EBITDA forecasts and reiterating a $510M-$535M 2026 EBITDA range. The company’s fundamentals are strengthened by healthy order entry and a sequentially higher $790M backlog, plus robust demand in ATMs, POS, SCO, and Smart Vision AI, including 26% Y/Y Retail sales growth in 1Q26 and notable Banking wins in North America, Europe, and India. Its low 1.2x net leverage, ~$680M liquidity, $21M of 1Q26 FCF, and expected 2026 FCF of $255M-$270M support buybacks and provide financial flexibility as Services margins improve and FCF remains well above adj. net income.

Bears say

Diebold Nixdorf is facing a cautious near-term setup because its 1Q26 adjusted EBITDA estimate was cut by $5M to $90M, reflecting weaker Services gross margin from remaining Oracle Field Services deployment and training costs in North America. While full-year 2026 and 2027 estimates were unchanged, the need to trim quarterly profitability highlights ongoing execution pressure, especially as Banking upgrade and replacement activity can be lumpy and unpredictable. The bearish view is reinforced by external risks from tariffs, supply-chain disruptions, FX volatility, and concentrated ownership, with only about 150K shares traded daily and roughly 60% of common shares held by debtholders.

DBD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Diebold Nixdorf Inc (DBD) Forecast

Analysts have given DBD a Buy based on their latest research and market trends.

According to 2 analysts, DBD has a Buy consensus rating as of Oct 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Diebold Nixdorf Inc (DBD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.